Takeda's 2026 Sustainability Performance: Climate Progress, Pharmaceutical Responsibility and the Challenge of Value Chain Decarbonisation

Japan-based Takeda Pharmaceutical Company Limited is one of the world's major research-driven biopharmaceutical companies, operating in approximately 80 countries and regions with around 50,000 full-time employees. Founded in 1781, Takeda focuses on gastrointestinal and inflammatory diseases, neuroscience, oncology, rare diseases, plasma-derived therapies and vaccines.

Takeda reported approximately US$28.3 billion in revenue for the fiscal year ended 31 March 2026. Its global manufacturing footprint, research activities and extensive supply chain create sustainability exposures extending well beyond its direct operations.

An examination of Takeda's 2026 Annual Integrated Report and ESG Databook reveals an ESG strategy increasingly connected to operational resilience, patient access, environmental management and scientific innovation. The central question is whether improvements in internal performance can translate into measurable sustainability outcomes across its wider pharmaceutical value chain.

Reporting Background and Regulatory Context

Takeda's 2026 disclosures cover fiscal year 2025, from 1 April 2025 to 31 March 2026. The company combines a strategic Annual Integrated Report with a more detailed ESG Databook containing quantitative indicators, calculation methodologies and selected independently assured information.

Its disclosures reference the IFRS Integrated Reporting Framework, the Sustainability Accounting Standards Board's Biotechnology & Pharmaceuticals standard, industry-specific investor guidance and United Nations Global Compact principles.

This structure is relevant as sustainability reporting increasingly moves towards financially material risk assessment, comparable metrics and verifiable information. Japan's Sustainability Standards Board of Japan (SSBJ) framework, alongside international IFRS Sustainability Disclosure Standards, provides an important direction for future reporting development.

For a multinational pharmaceutical company, European sustainability reporting developments, including CSRD and associated ESRS requirements, may also influence subsidiary reporting and value chain information requests. However, the reports do not establish that Takeda is subject to a particular CSRD reporting obligation. Applicability depends on the relevant legal entities, thresholds, exemptions and implementation timetable.

Governance Architecture and Accountability

Takeda describes a governance structure anchored in its Board of Directors and Takeda Executive Team. At the time of publication, eight of its 11 directors were external, including the board chair, representing approximately 73% of board membership.

The board oversees corporate strategy and major decisions, supported by nomination, compensation and audit-related governance arrangements. Director expertise includes medicine, regulation, sustainability, finance and digital technologies.

Takeda also maintains compliance frameworks addressing business ethics, human rights, data protection and responsible innovation. Its Takeda Ethics Advisory Council incorporates independent external expertise when considering complex ethical issues associated with scientific and technological developments.

These arrangements demonstrate the institutional integration of sustainability-related responsibilities. Nevertheless, the effectiveness of governance is better evaluated through evidence of oversight, management decisions, escalation mechanisms and measurable outcomes than through board composition alone.

Materiality Approach and Risk Prioritisation

Takeda organises its sustainability commitments around patients, people, the planet and values-based governance. Its reporting identifies access to medicines, employee development, decarbonisation, natural resources, product quality and ethical conduct as recurring priorities.

The company's reporting methodology states that content is selected based on its actual or potential impact on stakeholders and communities. This indicates an impact-oriented approach to identifying sustainability topics.

However, the two reviewed publications do not present a complete ESRS-style double materiality assessment documenting impact materiality and financial materiality through disclosed scoring thresholds and individual risk-and-opportunity conclusions.

This distinction matters because double materiality requires assessment of both organisational impacts on people and the environment and sustainability-related financial risks and opportunities. Takeda's disclosures provide a foundation for such analysis, but the publications alone do not demonstrate full conformity with ESRS double materiality assessment requirements.

Climate, Supply Chain and Social Dimensions

Climate performance is among Takeda's most quantitatively developed ESG areas. The company reports a 58% reduction in market-based Scope 1 and 2 emissions against its FY2016 baseline, compared with a 65% reduction target for FY2030.

Its Scope 3 emissions have declined by 10% against FY2022, while the company targets a 25% reduction by FY2030. Scope 3 represents approximately 90% of Takeda's total greenhouse gas emissions, making supplier engagement and logistics decarbonisation central to its longer-term objectives.

Takeda reports measures including renewable electricity procurement, facility electrification, transport optimisation and supplier collaboration. In FY2025, renewable electricity represented 93% of purchased electricity, according to the ESG Databook.

The challenge is that value chain decarbonisation depends partly on suppliers and other commercial partners outside Takeda's direct operational control. Takeda's Supplier Code of Conduct addresses environmental management, labour rights, safety and other requirements, supported by supplier assessments and independent audits. Greater disclosure of supplier assessment coverage, corrective-action outcomes and primary emissions-data quality would further strengthen evaluation of implementation.

Employment and Workforce Development

Takeda's workforce strategy emphasises employee engagement, inclusion, leadership development and digital capabilities. Its FY2025 employee engagement score increased from 76 to 79 on a 100-point scale, while its employee well-being score rose from 68 to 70.

Women represented approximately 53% of the reported workforce, while men accounted for 47%, with a small proportion identifying as other or non-binary. These figures describe overall workforce composition rather than representation across individual management levels.

The company also reports investment in workforce digital transformation. Approximately 63% of employees were actively using generative artificial intelligence tools, and employees completed 30,000 learning hours focused on future-ready digital skills.

These indicators suggest growing organisational capacity to adopt new technologies. Yet employee engagement, workforce diversity and technology adoption should be evaluated separately from productivity gains, equitable career development and the quality of employment outcomes. Continued reporting on leadership representation, retention and skills development would support deeper assessment.

Occupational Health and Safety

Occupational health and safety carries particular importance in pharmaceutical manufacturing, laboratories, plasma collection and related operations. Takeda reports safety metrics using defined methodologies and operational reporting boundaries.

Its FY2025 Total Recordable Incident Rate was 1.65, compared with 1.69 in FY2024. The Lost Time Incident Rate remained at 0.44, while no work-related fatalities were reported in either year.

The improvement in recordable incidents is positive, although relatively modest. An unchanged lost-time incident rate suggests that workplace safety performance requires continued attention rather than assumptions of sustained improvement.

Takeda's ESG Databook explains the calculation methods, including alignment of recordability criteria with relevant US Occupational Safety and Health Administration definitions. Transparent methodologies improve interpretation, but meaningful cross-company comparisons still require consistent workforce boundaries and incident classifications.

Product and Service Responsibility

Product responsibility is a particularly material ESG issue for pharmaceutical manufacturers because product quality, clinical trial ethics and medicine availability have direct consequences for patient health.

Takeda reports that 100% of applicable clinical trial summary results were disclosed within its defined reporting timeframe. It also reported that 100% of reviewed health authority Good Manufacturing Practice inspections resulted in no specified regulatory compliance actions.

The company reviewed approximately 500 health authority inspections globally during FY2025. These results indicate strong performance against its defined quality and transparency indicators, although they should not be interpreted as proof that all product or regulatory risks have been eliminated.

Patient access is another dimension of product responsibility. Takeda reported 2,104 newly enrolled patients in its affordability-based Patient Assistance Programs and a 99.6% on-time-in-full product dispatch rate. Together, these measures connect research and development with access, affordability and dependable supply, although patient-assistance enrolment does not by itself establish overall affordability across markets.

Philanthropy and Community Investment

Takeda's philanthropic activities place substantial emphasis on healthcare access and the resilience of health systems, particularly in lower-income countries.

During FY2025, its Global Corporate Social Responsibility Program announced JPY4.6 billion in multiyear funding for four nonprofit organisations supporting climate-resilient healthcare. Initiatives include medical supply chain improvements in Kenya and Somalia, healthcare waste management in Bangladesh and energy resilience for hospitals in parts of West Africa.

In the United States, Takeda reported US$16.4 million invested in community partnerships, with additional employee donations and matching contributions of US$7.6 million. Its community initiatives address healthcare access, nutrition and education.

These activities illustrate a connection between corporate philanthropy and pharmaceutical-sector sustainability challenges. However, intended beneficiaries and reported programme reach should not automatically be treated as independently verified improvements in health outcomes. Stronger longitudinal impact measurements would help distinguish programme activity from enduring community benefits.

Metrics, Targets and Data Robustness

Takeda's ESG Databook provides detailed quantitative information, including organisational boundaries, emissions accounting methodologies and selected historical comparisons.

The company reported approximately 2.81 million metric tonnes of CO₂-equivalent emissions in FY2025, incorporating Scope 1, market-based Scope 2 and the Scope 3 emissions presented in its inventory. Market-based Scope 1 and 2 emissions totalled approximately 274,000 tonnes.

Performance is more mixed across resource-management indicators. Waste diverted from landfill declined from 75% to 74%, while freshwater withdrawal reduction against the FY2019 baseline narrowed from 8.6% in FY2024 to 6% in FY2025.

These movements demonstrate why ESG progress should not be assessed through climate headline indicators alone. Although emissions performance improved, water and waste results show that environmental improvements are not uniform. The detailed Databook is particularly useful because it enables readers to identify these differences rather than relying exclusively on strategic narratives.

Assurance, Credibility and Comparability

An important element of Takeda's reporting is its external assurance process. KPMG AZSA Sustainability Co., Ltd. provides limited assurance over selected non-financial performance metrics identified in the ESG Databook.

The assurance engagement references ISAE 3000 (Revised) and ISAE 3410. Its conclusion concerns whether the selected information has been prepared, in all material respects, according to the criteria described by Takeda.

This distinction is important: limited assurance over selected indicators is not equivalent to assurance over the entire Integrated Report or every ESG claim. Readers should identify the precise assured metrics and reporting boundaries before drawing conclusions about reliability.

Looking ahead, ISSA 5000 offers an international framework for sustainability assurance engagements. Takeda's established assurance processes may provide relevant experience for future developments, but adopting a different assurance standard would require its own assessment of engagement scope, criteria and applicable requirements.

Strategic Implications for the Pharmaceutical Sector

Takeda's disclosures illustrate how pharmaceutical sustainability is evolving beyond traditional environmental compliance and corporate philanthropy.

First, Scope 3 emissions make pharmaceutical decarbonisation increasingly dependent on procurement, contract manufacturing, packaging and logistics. Second, nature-related considerations are becoming more prominent. Takeda reports its first Taskforce on Nature-related Financial Disclosures (TNFD) statement in 2026, alongside actions on water risk, waste and sustainable packaging.

Third, the sector faces growing expectations to demonstrate responsible innovation, particularly as artificial intelligence becomes more extensively integrated into research and operational processes. Takeda's responsible AI principles and ethics governance provide examples of how these issues may enter sustainability oversight.

Finally, patient access and medicine availability remain distinctive social priorities for pharmaceutical companies. General ESG frameworks may not fully capture these industry-specific impacts without supplementary measures addressing affordability, clinical transparency, treatment availability and product quality.

ESG Maturity and Future Positioning

Takeda's reporting demonstrates several characteristics associated with a developed ESG management system: board-level governance, quantified targets, historical performance information, industry-specific indicators and independent assurance over selected data.

Its more advanced disclosure areas include greenhouse gas accounting, medicine supply reliability, clinical trial transparency and workforce engagement. The complementary structure of its Integrated Report and ESG Databook also improves accessibility for readers seeking both strategic information and technical methodologies.

Nevertheless, future ESG maturity will depend increasingly on demonstrating implementation throughout the value chain. More granular disclosure of supplier due diligence outcomes, financial implications of sustainability risks, and nature-related dependencies would strengthen the relationship between sustainability performance and enterprise resilience.

Takeda has also announced that it will discontinue the separate Corporate Philosophy Metrics Framework from FY2026, while continuing annual ESG metric disclosures primarily through its Databook. Maintaining consistent metric definitions and historical comparability through this transition will be important for investors and other stakeholders.

Pacifica ESG View

Takeda's 2026 sustainability disclosures demonstrate a relatively developed approach to ESG measurement and accountability within the pharmaceutical industry. Its climate targets, externally assured indicators, product quality metrics and patient-access disclosures provide substantive evidence beyond broad sustainability commitments.

Nevertheless, progress is uneven. Scope 3 emissions remain the dominant climate challenge, while waste diversion and water withdrawal indicators moved in less favourable directions during FY2025.

The company's next test will be its ability to demonstrate measurable supplier-level improvements, clearer sustainability-related financial implications and consistent year-on-year disclosure following changes to its reporting framework. Takeda's reporting provides a useful benchmark, but its long-term ESG performance should continue to be judged by independently supported outcomes rather than commitments alone.

Implications for the wider market

Takeda's experience highlights several priorities for pharmaceutical and healthcare companies: strengthening Scope 3 data collection, embedding human rights and environmental requirements into supplier management, integrating climate and nature considerations, and improving independent assurance coverage.

For investors, sector-specific indicators such as medicine access, clinical trial transparency, manufacturing quality and supply continuity deserve attention alongside conventional climate and workforce metrics.

For sustainability leaders, the broader lesson is the importance of linking governance arrangements to consistent performance data and measurable outcomes. As reporting requirements and assurance expectations develop internationally, the ability to demonstrate credible implementation across complex pharmaceutical value chains is likely to become an increasingly important indicator of ESG maturity.

Download 2026 Annual Integrated Report

Download 2026 ESG Databook